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ABSTRACT
The brain cytoplasmic RNA, BC1, is a small
non-coding RNA that is found in different RNP par-
ticles, some of which are involved in translational
control. One component of BC1-containing RNP
complexes is the fragile X mental retardation
protein (FMRP) that is implicated in translational
repression. Peptide mapping and computational
simulations show that the tudor domain of FMRP
makes specific contacts to BC1 RNA. Endogenous
BC1 RNA is 20-O-methylated in nucleotides that
contact the FMRP interface, and methylation can
affect this interaction. In the cell body BC1 20-O-
methylations are present in both the nucleus and
the cytoplasm, but they are virtually absent at
synapses where the FMRP–BC1–mRNA complex
exerts its function. These results strongly suggest
that subcellular region-specific modifications of
BC1 affect the binding to FMRP and the interaction
with its mRNA targets. We finally show that BC1
RNA has an important role in translation of certain
mRNAs associated to FMRP. All together these
findings provide further insights into the
translational regulation by the FMRP–BC1 complex
at synapses.
INTRODUCTION
Absence of the fragile X mental retardation protein
(FMRP) causes the fragile X syndrome. FMRP is a
multi-functional RNA-binding protein with roles in local-
ization, translation (1,2) and stability of mRNAs (3,4). At
synapses, two FMRP complexes have been identiﬁed:
FMRP forms mRNPs with non-coding RNAs such as
the brain cytoplasmic RNAs BC1/BC200 (5,6) and the
miRNAs (7). FMRP interacts with BC1 RNA through
its N-terminal region shown to contain a novel
RNA-binding domain (8,9) containing two tudor motifs
(10). The tudor domain has been described to typically
recognize methylated amino acids (11). One activity of
FMRP is to repress local translation (1,2), a process
implicated in synapse maturation, learning and
memory (12).
BC1 RNA is a small non-protein coding RNA
(sncRNA) initially identiﬁed in rat brain (13,14) that is
highly expressed in neurons (15,16) and enriched at
synapses (17). BC1 RNA forms diverse ribonucleoprotein
particles (RNPs) with different protein partners including
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Staufen (20), Pur alpha and beta (21), poly(A)-binding
protein 1 (PABP1) (22,23), eIF4A (24) and hnRNPA2
(25). Some of the BC1 RNP particles are involved in
neuronal translational control as well; in particular, the
FMRP–BC1 complex represses translation of a deﬁned
subset of FMRP target mRNAs (5,6). In this context,
BC1 RNA acts as a bridging molecule between FMRP
and the substrate mRNAs (5,18) and helps recruiting add-
itional factors that are responsible for translation inhib-
ition (6).
We show here that BC1 RNA is 20-O-methylated in the
50-hairpin that is involved in mRNA translational regula-
tion in vivo (5). These 20-O-methylations are not detected
at synapses where absence of BC1 RNA affects translation
of some FMRP target mRNAs. Peptide mapping, molecu-
lar modelling and docking simulations showed that the
second tudor domain of FMRP recognizes the modiﬁed
region of BC1 RNA and surprisingly the 20-O-methyla-
tions affect the interaction of BC1 RNA with FMRP.
We propose that the 20-O-methyl modiﬁcations of BC1
RNA inﬂuence its activity in controlling translation at
synapses.
MATERIALS AND METHODS
Details of general molecular procedures, RNA quantiﬁca-
tion by RT–qPCR and the primer sequences used in this
study may be found in the Supplementary Data.
Animal care
Animal care was conducted conforming to the institution-
al guidelines that are in compliance with national and
European laws and policies. Mouse strains that have
been used in this study are: C57BL/6-129SV Wild-Type
(WT) and C57BL/6-129SV BC1 Knock-Out (KO). All
animals used in this study were 3 weeks old.
Detection of 20-O-methylations
20-O-methylation was analysed as previously reported
(26–28). Fifteen microgram of total RNA from WT
mouse brain or 2mg of synaptosomal RNA (highly
enriched for BC1 RNA, Supplementary Figure S1B)
were used for each primer extension assay with low
(4 and 2mM) or high (1mM) deoxyribonucleotide
triphosphate (dNTP) concentration. 20-O-methylation
creates a primer extension stop when the dNTPs are
limiting (4 and 2mM, Supplementary Figure S2A).
Avian Myeloblastosis Virus (AMV) reverse transcriptase
(Q-biogen) and radiolabelled primers were used in the
primer extension assays. Reverse transcription for RT–
qPCR reactions used the Moloney Murine Leukemia
Virus reverse transcriptase from Invitrogen. For the
sequence of the oligos used, see Supplementary Data.
RNA sequencing
Two hundred nanogram of BC1 and U2 transcripts were
sequenced using AMV reverse transcriptase (Q-biogen).
The RNAs were denatured for 10min at 70 C and
renatured for 10min on ice. The RT reactions were
performed at 45 C for 35min in the presence of 0.5mM
of each ddATP, ddGTP, ddCTP and ddTTP, and stopped
with blue/formamide buffer. The RNA was denatured for
1min at 90 C before being loaded onto an 8 M urea–10%
polyacrylamide gel. The gel was then dried and exposed
for 12 or 24h using a PhosphoImager screen (GE
Healthcare).
Expression of the FMRP-NT
Two separate sources of FMRP-N Terminus (FMRP-NT)
were used. Independent experiments were performed using
the FMRP protein domains prepared according to Zalfa
et al.( 9 ) , produced in house, and the same protein
domains produced by the Protein Expression and
Puriﬁcation Core Facility of the EMBL, Heidelberg.
Mutagenesis of the FMRP-N Terminus
In order to mutagenize the FMRP-NT, we used the Quick
Change Lightning Multi Site-Directed Kit (from Quiagen)
and the pET-M11-FMRP-NT plasmid which has the same
insert as described in (9), cloned into NcoI-KpnI site of
pET-M11 (EMBL protein expression group).
To generate the R70E-R11E double mutant, the DNA
oligos TV1 and TV2 were used. Mutagenized triplet is
shown in bold.
TV1: 50 -GGTTTATTCCGAAGCAAATGAAAAAG-30
TV2: 50 -GTCACAATTGAGGAGCTACGATCTG-30
To generate the Y103A-N104A double mutant, the
DNA oligo TV5 was used. Mutagenized triplets are
shown in bold.
TV5: 50- GTGATGCTACGGCTGCTGAAATTGTC
ACAATTG 30
The two mutagenized plasmids were sequenced before
use.
Electrophoretic mobility shift assay
BC1 RNA was in vitro transcribed in the presence of
a-[
32P] UTP using T7 RNA polymerase, or reconstituted
by ligation of [
32P]-labelled oligos in the presence of a
splint DNA oligo (29) (Supplementary Data). Directly
before use, RNAs were denatured/renatured in electro-
phoretic mobility shift assay (EMSA) buffer in the
presence of 1mg of tRNAs. Then, 1 10
5–2 10
5 cpm of
RNA (corresponding to 10 and 20fmol, respectively) were
incubated with 1–5 pmoles of FMRP N-terminus for
20min at room temperature in the presence of 150mM
KCl, 5mM MgCl2, 2mM DTT, 5% glycerol, 20mM
HEPES, pH 7.6 and 1mg yeast tRNA. The entire
reaction (20ml) was loaded on a native 1 TBE/6% acryl-
amide gel and run in 0.5  TBE from 2 to 4h at 170 V in a
cold room. The autoradiogram was recorded with a
PhosphorImager (GE Healthcare) and the bands were
quantiﬁed. From the equation Kd=([R][P]/[RP]) !
[RP]/[R]=[P]/ Kd, the ratio of [bound RNA]/[free
RNA] was plotted against [P], the slope giving 1/Kd.
Sucrose gradients to separate mRNPs and polysomes
Total mouse brain was homogenized in 3ml of lysis buffer
(10mM Tris–HCl pH 7.5, 100mM NaCl, 10mM MgCl2,
Nucleic Acids Research,2012, Vol.40, No. 9 40871% Triton X-100, 1mM dithiothreitol DTT, 30U/ml
RNasin). After 5min of incubation on ice, the extract
was centrifuged for 4min at 9300g at 4 C. The super-
natant (up to 0.5ml) was frozen in liquid N2 and either
stored at  80 C or immediately loaded onto a 15–50%
(w/v) sucrose gradient and centrifuged at 4 C for 1h
50min at 37000rpm in a Beckman SW41 rotor. Same
procedure was used to isolate Polysomes and mRNPs
from synaptoneurosomes. See Supplementary Data for
Polysome-mRNP analysis.
Synaptoneurosome preparation and RNA extraction
Synaptoneurosomes are particles containing both pre- and
postsynaptic compartments (30). Synaptoneurosomes
were prepared as previously described (6). Details can be
found in Supplementary Data.
Nuclear and cytoplasmic extracts
Cortices were weighed and resuspended in fractionation
buffer (75mg in 600ml). Nuclear and cytoplasmic
extracts were prepared using the PARIS kit according to
manufacturer’s recommendation (Ambion). RNA quality
control was performed using the Experion system
(Bio-Rad).
Immunoprecipitation followed by RT–PCR and
RT–qPCR analysis
Total brain and synaptosomes were lysed in 100mM
NaCl, 10mM MgCl2, 10mM Tris–HCl pH 7.5, 1%
Triton X-100, 1mM DTT, 40U/ml RNAse OUT
(Invitrogen), 10ml/ml Protease inhibitor cocktail
(Sigma-Aldrich), 5mM b-glycerophosphate, 0.5mM
Na3VO4. After 5min of incubation on ice, lysates were
centrifuged for 5min at 12000g at 4 C. The protein con-
centration was determined and the equivalent of 500mg
protein of the supernatant was used for the IP using
anti-FMRP antibodies (16) or puriﬁed rabbit IgGs as
negative control, and protein A Dynabeads (Invitrogen).
RT–PCR and RT–qPCR were performed as described in
Supplementary Data.
Mass spectrometric analysis of UV cross-links
The FMRP–BC1 particles (5nmol of FMRP-NT and
10nmol of BC1 RNA) were incubated in EMSA-binding
buffer for 15min on ice and irradiated on glass dishes at
254nm with four 8-Watt germicidal lamps (G8T5,
Herolab, Wiesloch, Germany) in parallel at a distance of
4cm for 2min on ice.
The reactions were diluted with buffer containing 1M
of urea, and digested with trypsin, RNase A and RNase
T1. Peptides cross-linked to an RNA moiety were
enriched on TiO2, and analysed by Electro Spray
Ionization Quadrupole Time Of Flight as described by
(31–33). Cross-linked peptides exhibit the combined
mass of the peptide and the RNA fragment; in the
Q-TOF sequencing, the cross-linked amino acid is
identiﬁed as the one where the sequencing ladder breaks
off.
Computational procedures
The MC-Sym web server (http://www.major.iric.ca/MC-
Sym/) has been used to generate the atomic structure of
the BC1 50-end RNA (34). As a template we used the BC1
50-hairpin 2D structure experimentally determined by
Rozhdestvensky and collaborators (35). This analysis,
i.e. the secondary structure determined by chemical and
enzymatic assays, revealed that BC1 RNA 50-domain has
an extended rod-like stem-loop structure. Details regard-
ing the molecular modelling and the molecular docking
procedures can be found in Supplementary Data.
RESULTS AND DISCUSSION
BC1 RNA represses translation of FMRP mRNA targets
at synapses
BC1 RNA is highly localized in dendrites and axons and it
is thought to regulate local protein synthesis (5,36).
Previous reports have shown a functional interaction
between BC1 RNA and FMRP at synapses (5,9,37,38).
To investigate the contribution of BC1 RNA to
FMRP-mediated translational regulation, we performed
polysome-mRNP gradient analysis. Cytoplasmic whole-
brain extracts from 3 weeks old WT and BC1 KO mice
(39) were fractionated on continuous sucrose gradients.
Figure 1A shows the sedimentation proﬁles for the two
genotypes. Fractions that contain actively translating
polysomes (P) and translationally silent mRNPs
(mRNPs), respectively, were pooled and the extracted
RNAs were used to determine the translational efﬁciency
by RT–qPCR (as percentage of mRNAs on polysomes,
PMP, Figure 1B) of Arc,  CamKII and Map1B mRNAs
that are translationally controlled by FMRP (5,40–44).
When the polysomal-mRNP analysis was carried out
from total brain, no increase in the PMP value was
observed for Arc,  CamKII and Map1B mRNAs
(Figure 1C). These data show that in total brain of BC1
KO animals, the translational efﬁciency of some FMRP
target mRNAs is not altered compared to WT
(Figure 1C).
We then investigated whether loss of BC1 RNA affects
mRNA translation at synapses. Synaptoneurosomes (30)
from WT and BC1 KO mice were prepared as previously
described (6). The quality of the preparations was veriﬁed
by the enrichment of synaptic proteins and RNAs
(Supplementary Figure S1A and S1B). The PMP of Arc,
 CamKII and Map1B mRNAs resulted higher in
synaptoneurosomes from BC1 KO animals than in their
WT littermates (Figure 1D), showing that these mRNAs
are more efﬁciently translated in the absence of BC1
RNA at synapses similarly to what we observed in
synaptoneurosomes from Fmr1 KO mice (5). Western
blot analysis conﬁrmed the increased level of proteins
encoded by those mRNAs at synapses (Figure 1F), mean-
while no protein increase is observed in total brain
(Figure 1E). These data suggest that BC1 RNA controls
the translation of three FMRP mRNA targets mainly at
synapses and this nicely coincides with the observation of
4088 Nucleic Acids Research, 2012,Vol.40, No. 9a translation dysregulation in synaptoneurosomes from
Fmr1 KO mice (5). These ﬁndings strongly suggest that
the FMRP/BC1 RNP exerts its major function at
synapses.
BC1 RNA is differentially 20-O-methylated in neurons
Post-transcriptional RNA modiﬁcations can have import-
ant roles in modulating its functions by inﬂuencing sec-
ondary and tertiary structure (45,46). Endogenous BC1
RNA was therefore isolated from mouse brain and
examined for the presence of 20-O-methylation, one of
the most common RNA modiﬁcations. The analysis was
performed on the BC1 50-hairpin that is implicated in the
interaction with FMRP and its target mRNAs (5,9).
We ﬁrst veriﬁed the efﬁcacy of the previously estab-
lished methodology (26–28) by analysing, in mouse
brain, the well-documented U2 snRNA 20-O-methylations
(47) (Supplementary Figure S2A). Using the BC1-speciﬁc
primers BMN155 and BMN297 (Figure 2A) and total
brain RNA, 20-O-methylations were clearly detected
in the 50-stem-loop at positions G46 (Gm46), C47
(Cm47) and G56 (Gm56) (Figure 2B and C: compare
lanes 5 and 6; 20-O-methylations are detected by strong
signals with less dNTPs, n=5). No 20-O-methylations
were observed using in vitro-transcribed BC1
RNA (Figure 2B and C, lanes 11 and 12 and lanes 7
and 8, respectively), or in the region located between the
two hairpins of the endogenous BC1 RNA (nucleotides
75–127, data not shown). Since the FMRP–BC1
complex controls mRNA translation at synapses (5,6)
(Figure 1D and F) we prepared synaptoneurosomes in
order to analyse the 20-O-methylation status of BC1
RNA at synapses. In this case, no 20-O-methylations
were detected on the synaptic BC1 RNA (Figure 2B
and C, compare lanes 13, 14 and 9 and 10, respective-
ly, n=4). The presence of intact BC1 RNA molecules
was veriﬁed by the presence of a stop of elongation at
nucleotide 1 of BC1 RNA (Supplementary Figure S2B).
Because BC1 RNA was found differentially 20-O-
methylated in the cell body versus the synapses, we
investigated its methylation status in the nucleus.
Nuclear and cytoplasmic compartments, used for this
analysis, were revealed by the presence and enrichment
for dyskerin and Glyceraldehyde 3-phosphate
Figure 1. BC1 RNA represses mRNA translation at synapses. (A) Cytoplasmic brain extracts from WT and BC1 KO mice were centrifuged through
a 15–50% sucrose gradient; absorbance at 254nm was monitored continuously and plotted against the fraction numbers. (B) Fractions 1–5,
corresponding to polysomes (P) and the fractions 6–10 containing mRNPs (mRNP) were pooled and further analysed by RT–qPCR.
(C) Translational efﬁciency of Arc,  CaMKII and Map1B mRNAs from WT (grey histograms) and BC1 KO (black histograms) mice were quantiﬁed
and expressed as PMP in the histograms. (D) Same as in panel (C) using synaptosomal preparation. Error bars represent SE: *P<0.05 or **P<0.01
for BC1 KO versus WT by Student’s test, n=4.(E) Protein levels of Arc,  CaMKII and Map1B from WT (in white) and BC1 KO (in black) from
total brain. (F) Same as in (E) using synaptic protein extracts. Error bars represent SE: *P<0.05 for KO versus WT by Student’s test, n=3.
Nucleic Acids Research,2012, Vol.40, No. 9 4089dehydrogenase (Supplementary Figure S1C). As shown in
Figure 2D, BC1 RNA from the cytoplasmic or nuclear
fractions is 20-O-methylated (compare lanes 7 and 8 and
lanes 9 and 10 for cytoplasmic and nuclear fraction, re-
spectively) underlining that absence of these 20-O-methy-
lations may have a function at synapses. These ﬁndings
suggest that BC1 20-O-methylations occur in nucleus.
To our knowledge this is the ﬁrst time that a non-coding
RNA is shown to be differently modiﬁed according to its
subcellular location.
BC1 RNA 20-O-methylations affect FMRP binding
Since the unmodiﬁed BC1 RNA is present at synapses,
where the FMRP–BC1 complex acts as a translational
inhibitor, we studied this interaction further.
The N-terminus of FMRP (FMRP-NT; residues 1–217)
contains two tudor domains (10), has RNA-binding
properties (8,48), and interacts directly with the BC1
50-hairpin (5,9). Because FMRP-NT tends to aggregate
(48) (and data not shown) we tested its correct folding
via the binding to the entire unmodiﬁed BC1 RNA
(Figure 3A and B) as well as to poly riboG and poly
riboC (data not shown). The FMRP-NT binds BC1
RNA with high afﬁnity (apparent Kd=128±22.7nM,
the same within experimental error as in ref. (9); see
Figure 3A for the gel and Supplementary Figure S3A
for the Kd plot). Furthermore, a similarly structured
RNA, U1 snRNA, was unable to compete with BC1
RNA for the FMRP binding (Figure 3B, compare lane 2
with lanes 4, 5 and 6).
In order to gain insights into the FMRP-NT/BC1 inter-
action, we cross-linked BC1 RNA to FMRP-NT by UV
exposure, enriched the tryptic peptides that were cova-
lently bound to RNA, and analysed them by mass
Figure 2. BC1 RNA is 20-O-methylated. (A) Primers used to detect BC1 RNA 20-O-methylations: BMN297, BMN155 are indicated on the BC1
secondary structure. (B) Low dNTP concentration primer extension analysis using the BMN155 primer on total brain RNA from WT mice (lanes 5
and 6), on the BC1 transcript (lanes 11 and 12), and on RNA from synaptoneurosomes (lanes 13 and 14). The arrows denote 20-O-methylations at
positions G46, C47. For each sample, the second lane shows the lower dNTP concentration; stops due to low dNTP indicate the presence of a 20-O-
methylation. Sequencing reactions are shown in lanes 1–4 and 7–10. (C) Same as in (B) using the BMN297 primer; sequencing (lanes 1–4), low dNTP
concentration primer extension analysis on total brain (lanes 5 and 6), on BC1 transcript (lanes 7 and 8) and on synaptosomal preparation (lanes 9
and 10). (D) Same as in (C) using total brain (lanes 5 and 6), cytoplasmic (lanes 7 and 8) and nuclear extracts (lanes 9 and 10).
4090 Nucleic Acids Research, 2012,Vol.40, No. 9Figure 3. Functional mapping of the FMRP-NT/BC1 interaction. (A) EMSA using the entire BC1 RNA without (lane 1) or with increasing amounts
of FMRP-NT (from 20 to 500ng, lanes 2–7). The asterisk denotes the shifted FMRP–BC1 complex. Arrowhead denotes unbound BC1 (free).
(B) Competition experiment using unlabelled U1 RNA. Lane 1 radiolabelled BC1 RNA, lane 2 radiolabelled BC1 and FMRP-NT (100ng, asterisk).
Lanes 4 and 6 show binding of FMRP-NT and BC1 RNA in the presence of 10–100-fold excess of unlabelled U1 RNA. Lanes 1 and 3 do not
contain FMRP-NT. (C) Identiﬁcation of FMRP residues that are in contact with BC1 RNA. The two tudor domains are underlined in black. The
tryptic peptides containing the cross-linked amino acids (highly reactive: E61 and C99, black dots) are shown in blue. (D) Docking model of the
interaction of FMRP-NT with the 50-end of BC1. The backbone of the tudor domains is shown in red, with the two cross-linked peptides highlighted
in blue. (E and F) Electrostatic and hydrogen-bond interactions of the FMRP-NT with BC1 RNA. FMRP is shown as a blue ribbon, and the lateral
chains of the amino acids involved in the binding network are indicated as blue sticks. The RNA is shown as grey molecular surface with the
nucleotides involved in the hydrogen bond and electrostatic network (orange spot), the 20-O-methylated atoms are shown as a yellow surface.
(G) EMSA using FMRP-NT (from 25 to 100ng) and unmodiﬁed BC1 RNA (lanes 2–5) or 20-O-methylated BC1 RNA (lanes 7–10). Lanes 1 and 6,
unbound BC1 RNA. The asterisk indicates the FMRP-NT/BC1 RNA complex. The histogram shows the ratio of the Kd of 20-O-methylated BC1
construct versus the Kd of unmodiﬁed BC1 construct. Error bars represent SE: **P<0.01, Student’s test, n=3.
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(31–33) in which mass spectroscopy sequencing identiﬁes
the cross-linked amino acid. The two amino acids that
cross-link to BC1 RNA are indicated in Figure 3C (E61
and C99, black dots) and are both situated in the second
tudor domain (underlined). Next we carried out a
molecular modelling of the BC1 RNA tertiary structure.
Based on this structure, the 3D structure of the ﬁrst 134
amino acids of FMRP-NT (10), and the cross-links
identiﬁed by mass spectrometry (Figure 3C, blue
peptides), we performed a molecular docking simulation
to generate a protein–RNA complex (Figure 3D). The
molecular docking simulation shows that the hypothesized
recognition between FMRP-NT and 50-end BC1 RNA is
stabilized through both salt bridges and hydrogen-bond
interactions. Speciﬁcally the FMRP residues R70, Y103,
N104 and R111 interact through hydrogen bonds with
the RNA nucleotides G31, C32, C45, G46, C47 and
A48 (Figure 3E, orange nucleotides and Supplementary
Table S1). Furthermore, salt bridge interactions occur
between the two arginines R70 and R111 and the phos-
phate groups of the nucleotides C47 and A48 (Figure 3E
and Supplementary Table S1). Importantly, two of the
three 20-O-methylated nucleotides (G46 and C47) are
directly involved in FMRP-NT binding while the third
(G56) is localized outside of this binding region. When
two methyl groups are added, by molecular modelling,
to the nucleotides G46 and C47 (Figure 3F, methyl
groups in yellow), signiﬁcant changes in the BC1 surface
occur that affect the interaction with FMRP-NT. In par-
ticular, the addition of 20-O-methylations increases the
steric hindrance and makes access of FMRP more difﬁcult
(Figure 3F). In order to characterize the effect of BC1 20-
O-methylations on FMRP binding, the BC1 50-hairpin was
synthesized in an unmodiﬁed or 20-O-methylated form,
ligated to the BC1 30-end (A-stretch plus 30-hairpin) to
constitute the entire BC1 RNA (Supplementary Figure
S3B) and tested for its ability to associate to FMRP-NT.
As shown in Figure 3G, the 20-O-methylated BC1 RNA
binds signiﬁcantly less to FMRP-NT (right panel: the Kd of
the 20-O-methylated BC1 RNA oligonucleotide is  10-fold
higher than the Kd of the unmodiﬁed one). 20-O-methyla-
tion of these nucleotides in the minimal FMRP-binding
domain of BC1 conﬁrmed these data (Supplementary
Figure S3C). We suggest that the 20-O-methylation critic-
ally alters the BC1 surface shape and, reducing the electro-
static interactions, decreases the afﬁnity between
FMRP-NT and BC1.
While the tudor domains of FMRP are necessary for
RNA binding, they are not sufﬁcient: another 83 amino
acids are needed to create the RNA-binding domain (9).
We could not model this extra domain with high conﬁ-
dence, because there are no reference structures showing
sufﬁcient identity in the databases. However, molecular
docking suggests that this domain might be able to form
additional contacts to the basis of the 50-hairpin. In par-
ticular, the helix-loop-helix (HLH) motif in this region
(10) might insert itself into the major groove of the
RNA region containing the third 20-O-methylated nucleo-
tide (G56), creating additional speciﬁc contacts
(Figure 3D and data not shown). It is thus the second
tudor domain of FMRP together with the adjacent
residues that creates a novel RNA-binding surface. A
crucial contribution to the binding comes from R70 and
R111 that form salt bridges to the negative charges of the
phosphates at positions 47 and 48. While these contacts
are formed by the tudor domain, its canonical methyl
binding site is not involved in the RNA binding.
Instead, the tudor domain serves as a scaffold that pos-
itions the amino acids on one site of the beta barrel in such
away that they can form speciﬁc interactions with the BC1
RNA.
Structural analysis of the FMRP-NT/BC1 interaction
According to the molecular docking simulation and the
experimental cross-linking data, the second tudor
domain gives an important contribution to the stability
of the FMRP-NT/BC1 complex. In order to verify this
model, two different FMRP-NT double mutants were
created. In the ﬁrst mutant the positive charge, carried
by the side chain of residues R70 and R111 (Figure 3E
and F), was reversed by mutating both the residues into
glutamic acid, while in the second mutant the hydrogen-
bond interactions of residues Y103 and N104 (Figure 3E
and F) were removed by mutating both residues into
alanines. The effect of these mutations was predicted by
docking simulation, comparing the HADDOCK score
(49) where a lower value predicts stronger binding.
The introduction of two alanines at positions 103 and
104 actually removes the hydrogen bonds formed by the
wild type residues (compare Figure 4A and C and see
Supplementary Table S1). Due to the reduced steric hin-
drance of the alanine residues, however, the FMRP
protein wraps more tightly around BC1 RNA improving
other energy terms in the HADDOCK score (i.e. the van
der Waals, the buried surface area, the binding and the
desolvation energies). The total score therefore decreases
from  38.0 in the WT to  49.0 in the mutant, predicting a
higher binding afﬁnity. The docking model was experi-
mentally validated by EMSA experiments with the
in vitro-transcribed unmodiﬁed BC1 RNA and the
mutant protein (produced in Escherichia coli;
Supplementary Figure S4A). As expected, the apparent
Kd decreases by a factor of 2.7 (Figure 4F, strong
tendency: P=0.07, n=5; apparent Kd FMRP NT
WT=128±22.7nM and Kd NT Mut=51±4.1nM)
showing the validity of the modelling. On the other
hand the reversion of the positive charges (R70E-R111E,
Figure 4A and B) repel the negatively charged phosphates
of the RNA backbone, leading to a change in the FMRP
orientation towards BC1 and thus to a considerable
decrease in the area of interaction surface (Figure 4B).
Therefore, the HADDOCK score increases from  38.0
to  25.0, showing a signiﬁcantly lower afﬁnity. Again
the docking prediction was veriﬁed by EMSA using the
mutant protein (Supplementary Figure S4B). The Kd
increased signiﬁcantly by a factor of 3.8 (Figure 4D,
P<0.01, n=3. Apparent Kd FMRP NT WT=
128±22.7nM and Kd FMRP NT Mut=488±12nM,
respectively). Competition experiments, using both un-
labelled BC1 and U1 RNAs, showed that the mutated
4092 Nucleic Acids Research, 2012,Vol.40, No. 9FMRP-NT/BC1 interaction remains speciﬁc (Figure 4E
and G). In conclusion the electrostatic interactions of
the two arginines R70 and R111 guide the interaction of
the second tudor domain with BC1 RNA. Interestingly the
binding partners of the two arginines are the phosphates
at the 30-side of the 20-O-methylated nucleotides G46
and C47.
The FMRP–BC1–mRNA inhibitory complex at synapses
To investigate if BC1 20-O-methylations have an effect on
the afﬁnity of FMRP for its mRNA targets, we
immunoprecipitated FMRP complexed with BC1 RNA
from total brain (Figure 5A, left panel). At ﬁrst, we moni-
tored that BC1 RNA was indeed associated to FMRP
(Figure 5A, right panel), together with a well-known
FMRP target ( CaMKII mRNA). The speciﬁcity of the
interaction is revealed by the absence of D2DR mRNA in
the FMRP complex (38). To address whether the BC1
bound to FMRP is 20-O-methylated or not, we performed
low dNTP primer extension assays from FMRP
immunoprecipitated RNAs (Figure 5B). Using the BC1-
speciﬁc primers, BMN155 and BMN297, the
Figure 4. Effect of R70, R111, N104, Y103 to the binding of BC1 RNA. (A–C) Docking models of the FMRP-NT WT, FMRP-NT R70E-R111E
and FMRP-NT Y103A-N104A interaction with BC1, respectively. The yellow RNA backbone represents the nucleotides involved in the interaction.
The key amino acids detected by mass spectrometry analysis are depicted as blue sticks. (D) EMSA experiment using BC1 RNA, FMRP-NT WT and
FMRP-NT R70E-R111E mutant (10–100ng). Shifted and unbound RNA are indicated by asterisk and arrowhead, respectively; the histogram shows
the ratio of the Kd of mutant FMRP-NT versus the Kd of WT FMRP-NT. Error bars represent SE: **P<0.01, Student’s test, n=3. (E)
Competition experiments using unlabelled BC1 (lanes 3–5) and U1 (lanes 6–8) transcripts. (F) and (G) The same as in (D) and (E) but using the
Y103A-N104A mutant. P=0.07 Student’s test, n=5.
Nucleic Acids Research,2012, Vol.40, No. 9 409320-O-methylations were detected in the 50-stem-loop only
in the input RNA (Figure 5B, left and right panels:
compare lanes 5 and 6) while the BC1 immunoprecipitated
by FMRP was not 20-O-methylated (Figure 5B: compare
lanes 7 and 8). Since the in vitro data showed that FMRP
binds less efﬁciently to 20-O-methylated BC1 RNA (Figure
3G, Supplementary Figure S3C), we wanted to investigate
if the presence or absence of 20-O-methylations on BC1
RNA had also an effect on stabilizing FMRP target
mRNAs in the complex. To address this point we
immunoprecipitated FMRP from total brain and
synaptoneurosomal extracts and detected the associated
mRNAs in the complex. RT–qPCR assays showed a
higher co-immunoprecipitation efﬁciency of FMRP
target mRNAs/RNA ( CamKII, Arc, Map1B, BC1)i n
synaptoneurosome preparations versus total brain
(Figure 5C, Supplementary Figure S5). Since at synapses
BC1 is mainly detected in the non-methylated form, these
ﬁndings suggest that absence of 20-O-methylations favours
the FMRP–BC1–mRNA association. Importantly,
this complex has been previously shown in vivo to
inhibit mRNA translation at synapses (5,6) and Figure
1D and F).
In conclusion, in this study, we show that (i) BC1 is
differentially 20-O-methylated according to its subcellular
location. (ii) The tudor domain of FMRP, with its
RNA-binding activity, binds FMRP recognizing the 20-
O-methylation status of BC1 RNA. (iii) At synapses,
where BC1 RNA is not 20-O-methylated, the FMRP–
BC1–mRNA interaction is increased. (iv) At synapses
BC1 regulates the translation of some FMRP target
mRNAs.
Figure 5. At synapses, where BC1 is mainly unmethylated, FMRP binds its mRNA targets with higher afﬁnity. (A) Immunoprecipitation of
FMRP-associated mRNAs/RNA. Left panel, Western blot of FMRP immunoprecipitated from total brain extracts. Input (1/10), FMRP IP
(1/3), the IgG IP (1/3). Right panel, RT–PCR from immunoprecipitated RNA derived from the input (1/10), IgG IP (2/3) and FMRP IP (2/3).
The arrow points to the primers used to amplify BC1 RNA (B) Upper panel, low dNTP concentration primer extension analysis using the BMN155
primer on total brain RNA (Input, lanes 5 and 6) and immunoprecipitated BC1 RNA (lanes 7 and 8, n=5). The arrows denote 20-O-methylations at
positions G46, C47. For each sample, the second lane shows the lower dNTP concentration. Sequencing reactions are shown in lanes 1–4. Lower
panel as upper panel using the BMN297 primer able to detect the 20-O-methylation on the G56, n=3.(C) Enrichment of FMRP mRNA targets in
immunoprecipitated FMRP complex from both total brain and at synapses. RT–qPCR of FMRP co-immunoprecipitated mRNAs/RNA. Shown is
the ratio of the RNA precipitated using FMRP and rabbit unspeciﬁc IgGs from total (white histogram) and synaptoneurosomes (grey histogram)
brain extracts, each normalized for the respective input. Error bars represent SE: **P<0.01, Student’s test, n=3.
4094 Nucleic Acids Research, 2012,Vol.40, No. 9At structural level, methylation of the sugar
20-OH-group favour the 30-endo conformation which sta-
bilize helical conformations (46). It is possible to envision
that the endo-conformation affects the binding to a given
protein. In a highly complex cell like the neuron, which
undergoes many changes during brain development, elab-
orate and ﬁne-tuned mechanisms are required to regu-
late gene expression. We propose that changes in the
20-O-methylation status of BC1 RNA contribute to the
regulation of synaptic gene regulation and consequently
neuronal plasticity.
These ﬁndings provide new insights into translational
control at synapses and suggest that RNA modiﬁcations
could have an important inﬂuence in genetic brain disease,
a heretofore unknown relationship.
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